Fall 2012
OUTREACH
7
Trial Title
Locations*
Eligibility
Phase III Study of Chemotherapy and
Chemoradiotherapy with or without HyperAcute®-
Vaccine for Surgically Resected Pancreatic Cancer
66
trial sites throughout
the United States
Patients must have undergone surgical resection
for pancreatic adenocarcinoma. First vaccination
must occur within 10 weeks following surgery.
Phase II Study Using Short-Term Cultured, CD8+
Enriched Autologous Tumor-infiltrating Lymphocytes
in Metastatic Digestive Tract Cancers
1
trial site throughout the
United States
Open to patients with metastatic pancreatic,
gastric, gastro-esophageal, hepatocellular,
gallbladder carcinomas and cholangiocarcinoma.
Phase II Study of the Sequential Administration of
GVAX Pancreas Vaccine Alone or Followed by CRS-
207 (
Listeria-based) Vaccine in Metastatic Pancreatic
Adenocarcinoma
10
trial sites throughout
the United States
Patients must have metastatic pancreatic
adenocarcinoma.
Phase II Trial of Boost Vaccinations of a Lethally
Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine
Transfected with the GM-CSF Gene in Resected
Pancreatic Adenocarcinoma
1
trial site throughout the
United States
Patients must have undergone the Whipple
surgery for pancreatic adenocarcinoma within 18
months and completed adjuvant chemotherapy
and/or chemoradiation. No prior vaccine/
immunotherapy treatment for pancreatic cancer
allowed.
Phase I/II Study using Anti-mesothelin Modified
Lymphocytes in Pancreatic Cancer, Mesothelioma
and Other Metastatic Cancers Expressing Mesothelin
1
trial site throughout the
United States
Patients must have metastatic or unresectable
(
inoperable) pancreatic cancer.
Phase I Study of Vaccine Therapy (PANVAC) and
GM-CSF in Locally Advanced Pancreatic Cancer that
Cannot Be Removed by Surgery
1
trial site throughout the
United States
Patients must have locally advanced unresectable
(
inoperable) pancreatic adenocarcinoma or
metastatic disease of small volume.
Phase I Study of Vaccination with Poly-ICLC
(
Hiltonol) and Peptide-Pulsed Dendritic Cells in
Metastatic Pancreatic Adenocarcinoma
1
trial site throughout the
United States
Patients must have metastatic pancreatic
adenocarcinoma.
Pilot trial of a Vaccine Therapy (GVAX) with or
without Cyclophosphamide in Patients Undergoing
Chemotherapy and Radiation Therapy for Resected
Pancreatic Cancer
1
trial site throughout the
United States
Newly diagnosed patients with stage I or II
pancreatic adenocarcinoma. Patient must be a
candidate for the Whipple procedure.
Pilot Study Evaluating GVAX Vaccine and Low Dose
Cyclophosphamide Integrated with Fractionated
Stereotactic Body Radiation Therapy (SBRT)
and FOLFIRINOX Chemotherapy in Patients with
Resected Adenocarcinoma of the Pancreas
1
trial site throughout the
United States
Patients must have undergone surgical resection
for pancreatic adenocarcinoma. No prior
treatment for pancreatic cancer allowed.
Vaccine Clinical Trials Currently Enrolling Pancreatic Cancer Patients
CLINICAL TRIALS: A VITAL STEP IN MAKING PROGRESS
The Pancreatic Cancer Action Network recommends that all patients consider clinical trials when exploring treatment options.
The Pancreatic Cancer Action Network’s Patient and Liaison Services (PALS) program maintains a comprehensive database
containing up-to-date information about pancreatic cancer clinical trials taking place throughout the United States. For
a personalized clinical trials search or for other questions related to clinical trials, contact a PALS Associate toll-free at
877-272-6226
or email
pals@pancan.org
. PALS Associates are available Monday-Friday, 7am-5pm Pacific Time.